Tachykinins protect cholinergic neurons from quinolinic acid excitotoxicity in striatal cultures

The neuroprotective effect of tachykinins against excitotoxic death of cholinergic neurons was studied in rat striatal cell cultures. Quinolinic acid (QUIN) and kainic acid (KA) produced a dose dependent decrease in choline acetyttransferase activity, but KA was more potent. Our results show that substance P (SP) totally reversed the toxicity induced by 125 μM QUIN but not by 40 μM KA. This effect was also observed using protease inhibitors or a SP-analog resistant to degradation, [Sar⁹]-Substance P. The survival of neuron specific enolase- and acetylcholinesterase (AChE)-positive cells after treatment with QUIN alone or in the presence of SP was also examined. We observed that, while a decrease in total cell number produced by QUIN was not prevented by SP treatment, AChE-positive cells were rescued from the toxic damage. To characterize the SP protective effect we used more selective agonists of the three classes of neurokinin (NK) receptors. [Sar⁹, Met(O₂)¹¹]-Substance P (NK₁ receptor agonist), [Nle¹⁰]-Neurokinin A (NK₂ receptor agonist) or [Me-Phe⁷]-Neurokinin B (NK₃ receptor agonist) were all able to block the toxic effect of QUIN on cholinergic activity. These results show that tachykinins provide an important protective support for striatal neurons, suggesting a possible therapeutical benefit in neurodegenerative disorders affecting cholinergic neurons.     

Substance P (neurokinin-1) receptor mRNA is selectively expressed in cholinergic neurons in the striatum and basal forebrain

In the striatum substance P (neurokinin-1) receptor, mRNA is selectively localized in large neurons that also express mRNA encoding choline acetyltransferase (ChAT) by in situ hybridization histochemistry. Substance P receptor mRNA is also localized in ChAT mRNA-containing neurons in the medial septum and basal forebrain cell groups. Thus, in the rat forebrain the substance P receptor appears to be expressed selectively by cholinergic neurons. Striatal neurons that contain substance P also utilize γ-aminobutyric acid (GABA) as a transmitter. These neurons make synaptic contact with striatal cholinergic neurons, which are shown here to express the substance P receptor, and with other GABAergic neurons in the striatum and substantia nigra, which express GABA receptors but not substance P receptors. This suggests that individual striatal neurons may differentially affect target neurons dependent on the receptors expressed by those target neurons.     

A2A adenosine receptor antagonists protect the striatum against rotenone-induced neurotoxicity

Adenosine A2A receptor has emerged as an attractive non-dopaminergic target in the experimental pharmacological therapy for Parkinson's disease (PD). Moreover, it has been postulated that A2A adenosine receptor antagonists exert neuroprotective effects in experimental models of PD and progressive supranuclear palsy (PSP). Interestingly, in both these pathological conditions a deficit of mitochondrial complex I has been found. Thus, utilizing extracellular and intracellular recordings from corticostriatal brain slices, we have tested the possible neuroprotective action of two A2A receptor antagonists, ST1535 and ZM241385, on the irreversible electrophysiological effects induced by the acute application of rotenone, a pesticide acting as a selective inhibitor of mitochondrial complex I activity. Both these antagonists reduced the rotenone-induced loss of corticostriatal field potential amplitude as well as the membrane depolarization caused by this toxin on striatal spiny neurons. The use of A2A receptor antagonists might represent a promising neuroprotective strategy in basal ganglia disorders involving a deficit of mitochondrial complex I activity.     

Partial purification of a pramipexole-induced trophic activity directed at dopamine neurons in ventral mesencephalic cultures

We previously demonstrated that media conditioned by exposure to ventral mesencephalic (VM) cultures in the presence of pramipexole (PPX) and other drugs with dopamine (DA) D₃ properties, increased the growth and survival of DA neurons in recipient VM cultures. This trophic activity was heat-labile and not present in parietal cortex cultures or cultures pretreated with the DA neuron toxin MPP⁺. In an effort to begin to identify the protein(s) responsible for this trophic effect, we compared the conditioned media from normal VM cultures, VM cultures incubated with PPX, and VM cultures pretreated with MPP⁺ and treated with PPX. Neutralization studies using anti-GDNF and anti-BDNF failed to reduce the conditioned media transfer effect, and Millipore Ultrafree centrifugation studies placed the mol.wt. of the activity around 30 kDa. SDS separation revealed three potential bands of interest. A 35-kDa band was present in normal cultures, increased in PPX-incubated cultures, and absent in MPP⁺-pretreated/PPX-incubated cultures. This conforms to the effect the protein concentrates used to produce these gels had on the growth of DA neurons in VM cultures. Since VM cultures grown in neural basal media, which inhibits the growth of glia, still responded to PPX in a dose-dependent fashion, the trophic activity may be a DA autotrophic factor. However, the gels also revealed two bands at 31 and 55 kDa that were reduced by exposure to PPX and present in MPP⁺-pretreated cultures. The possibility that these are neuroinhibitory factors that are also regulated by PPX therefore cannot be ruled out.     

A 35 kDa Fos-related antigen is co-localized with substance P and dynorphin in striatal neurons

The rat striatum after dopamine denervation followed by repeated apomorphine treatment was examined for the co-expression of c-fos and Fos-related antigens with dynorphin, substance P and [Met5]enkephalin using Western blot and immunohistochemical techniques. Administration of apomorphine, a dopamine agonist, elevated the level of 35 kDa Fos-related antigen which co-localized with dynorphin and substance P, but not enkephalin, in striatal neurons.     

The direction of apomorphine-induced rotation behavior is dependent on the location of excitotoxin in the rat basal ganglia

Adult rats received unilateral kainic acid (KA) lesions of the striatum with the anterior/posterior coordinates of the lesion at either 1.5 mm or 0.3 mm anterior to bregma. Four to six weeks after the lesion rats were placed in an open field environment and injected with apomorphine (1 mg/kg, s.c). Rats receiving the more posterior lesion (0.3 mm) rotated ipsilateral to the lesioned side of the brain. In contrast, the majority of rats receiving the more anterior (1.5 mm) placement of the lesion rotated contralateral to the lesioned side of the brain. Histological analysis of several animals receiving posterior lesions revealed damage to the hippocampus and thalamus that was not seen in the animals receiving anterior lesions. Our results are consistent with the hypothesis that the direction of apomorphine-induced rotation after excitotoxin injection into the rat basal ganglia is dependent on the location of the lesion.     

Opposite presynaptic regulations by glutamate through NMDA receptors of dopamine synthesis and release in rat striatal synaptosomes

Purified striatal synaptosomes were superfused continuously with L-[3,5-³H]tyrosine to measure simultaneously the synthesis ([³H]water formed during the conversion of [³H]tyrosine into [³H]DOPA) and the release of [³H]dopamine ([³H]DA). Glutamate (10⁻³ M) and NMDA (10⁻³ M, in the absence of Mg²⁺) stimulated the release of [³H]DA, but they reduced the efflux of [³H]water. This reduction of [³H]DA synthesis was blocked by 2-amino-5-phosphonovalerate indicating the involvement of NMDA receptors. Although D,L--amino-3-hydroxy-5-methyl-4-isoxazole-4-propionate (AMPA) and kainate stimulated the release of [³H]DA, they did not affect its synthesis. The glutamate-evoked inhibition of [³H]DA synthesis was prevented when synaptosomes were superfused continuously with adenosine adenosine deaminase plus quinpirole, a treatment which markedly reduces the phosphorylation of tyrosine hydroxylase by cAMP dependent protein kinase. The opposite effects of glutamate on [³H]DA synthesis and release were mimicked by ionomycin (10⁻⁶ M). It is proposed that both an activation of a cyclic nucleotide phosphodiesterase and a dephosphorylation of tyrosine hydroxylase linked to the influx of calcium through NMDA receptors is responsible for the inhibition of dopamine synthesis by glutamate and that calcineurin could play a critical role in these processes.     

Substance P receptor desensitization in the dorsal horn: possible involvement of receptor-G protein complexes

The repeated administration of a high dose of substance P (SP) onto the spinal cord has been shown to attenuate behavioral response to an intense heat (tail-flick) or noxious mechanical stimulus (paw pressure). Studies performed to investigate the action of spinal SP have suggested that changes in behavioral responses involve endogenous opiate or neurokinin systems. This study was performed to investigate whether the binding characteristics of SP receptors in the dorsal horn are altered following successive administration of SP. Two populations of [³H]-SP binding sites were distinguished on the basis of their binding affinity. Gpp(NH)p, a stable analogue of GTP, decreased the size and affinity of the high affinity binding component selectively labelled with [¹²⁵I]-Bolton Hunter-SP. Repeated intratehcal administration of SP (15 μg) which reduced behaviors also reduced the number and affinity binding sites. Thus, attenuated behaviors in response to repeated administration of SP are paralleled by an alteration of SP binding in the dorsal horn. The altered agonist affinity seen under desensitizing conditions raises the possibility that SP receptor desentization involves an uncoupling of receptor-G protein complexes.     

Cortical stimulation induces Fos expression in striatal neurons via NMDA glutamate and dopamine receptors

Cortical electrical stimulation has been shown to induce dense and widespread Fos expression throughout the ipsilateral and contralateral striatum. This raises interest for studying the mechanisms underlying the regulation of striatal neuron activity by cortical afferents, and for elucidating the interactions with other systems. However, the receptors mediating cortical-stimulation-induced expression of Fos in striatal neurons have not been identified. This was studied in the work reported here by stimulating the cortex after administration of glutamate or dopamine receptor antagonists, or after 6-hydroxydopamine (6-OHDA) lesion of the nigrostriatal dopaminergic system. Pretreatment with the non-competitive N-methyl- d-aspartate (NMDA) glutamate receptor antagonist MK-801 led to a marked reduction in the stimulation-induced density of Fos-immunoreactive nuclei in both the medial (about 80% reduction) and lateral (about 50–60% reduction) striatum. Preadministration of the D₁-selective dopamine antagonist SCH-23390 alone or in combination with the D₂-selective dopamine antagonist eticlopride led to a reduction in the stimulation-induced density of Fos-positive nuclei of about 60–65% in the lateral striatum, but no significant change in the medial region. The effects of 6-OHDA lesion were less pronounced, and the stimulation-induced density of Fos-immunoreactive nuclei decreased by only about 25% in the lateral region. These results indicate that both dopamine and NMDA glutamate receptors are involved in the induction of Fos by cortical stimulation, and support the hypothesis that cortex-dopamine interactions in the lateral striatum may be functionally different from those in the medial striatum.     

Neuroprotective effects of GDNF against 6-OHDA in young and aged rats

In young adult rats, glial cell line-derived neurotrophic factor (GDNF) can completely protect against 6-hydroxydopamine-induced loss of nigral dopamine neurons when administered 6 h prior to the 6-hydroxydopamine. The present study was undertaken to determine if GDNF would provide similar protective effects in aged rats. Male, Fischer 344 x Brown Norway hybrid rats of 3, 18 and 24 months of age were given an intranigral injection of GDNF or vehicle followed 6 h later with an intranigral injection of 6-hydroxydopamine. Nigral dopamine neuron cell survival, and striatal and nigral dopamine and DOPAC levels, were evaluated 2 weeks after the lesions. In vehicle treated animals cell survival on the lesioned side ranged from 15 to 27%. GDNF promoted significant cell survival in the nigra of all three age groups; however, the percent survival was lowest in the 24-month-old animals (85% at 3 months, 75% at 18 months, 56% at 24 months). Similarly, dopamine levels in the striatum and substantia nigra on the lesioned side remained significantly greater in the GDNF treated animals compared to the vehicle treated animals. As with the cell survival experiment, the protective effects of GDNF on dopamine levels were less in the 24-month-old animals. GDNF pretreatment also protected against 6-hydroxydopamine-induced reductions in striatal DOPAC levels in all age groups. Overall, these results indicate that GDNF can protect nigrostriatal dopamine neurons against the effects of 6-hydroxydopamine in aged as well as young adult rats. However, the extent of protection is less in the aged (24-month-old) animals.     

Nicotine releases stereoselectively and Ca-dependently endogenous 3,4-dihydroxyphenylalanine from rat striatal slices

In superfused slices of rat striatum, nicotine-evoked release of endogenous 3,4-dihydroxyphenylalanine (DOPA) was studied in comparison with that of dopamine (DA). (if(±)-Nicotine (0.1–10 μM) constantly and repetitively released DOPA and DA over a similar time course in a concentration-dependent manner. The ratio of DOPA and DA evoked was approximately 1:2–3. The turnover rate of DOPA was about 300 times higher compared to DA. (±)-Nicotine (10 μM)-induced DOPA release was mecamylamine (20 μM)-sensitive, Ca²⁺-dependent and tetrodotoxin (0.3 μM)-insensitive. The (+)-isomer induced no DOPA release. These characteristics of DOPA release were almost the same as those of DA. Nicotine evokes endogenous DOPA via nicotinic cholinergic receptors in a manner similar to the transmitter DA. These findings further support a probable role of DOPA as a neuroactive substance in the rat central nervous system.     

Electrophysiological actions of zonisamide on striatal neurons: Selective neuroprotection against complex I mitochondrial dysfunction

Since the anti-epileptic drug Zonisamide (ZNS) seems to exert beneficial effects in Parkinson's (PD) disease, we have investigated the electrophysiological effects of ZNS in a rat corticostriatal slice preparation. ZNS affected neither the resting membrane potential nor the input resistance of the putative striatal spiny neurons. In contrast, this drug depressed in a dose-dependent manner the current-evoked repetitive firing discharge with a EC₅₀ value of 16.38 μM. ZNS also reduced the amplitude of glutamatergic excitatory postsynaptic potentials (EPSPs) with a EC₅₀ value of 32.5 μM.Reduced activity of the mitochondrial respiratory chain, particularly complex I and II, is implicated in the pathophysiology of PD and Huntington's (HD) diseases, respectively. Thus, ZNS was also tested in two different in vitro neurotoxic models obtained by acutely exposing corticostriatal slices either to rotenone, a selective inhibitor of mitochondrial complex I, or to 3-nitropropionic acid (3-NP), an inhibitor of complex II. Additionally, we also investigated the effect of ZNS in an in vitro model of brain ischemia. Interestingly, low concentrations of ZNS (0.3, 1, 3 and 10 μM) significantly reduced the rotenone-induced toxicity protecting striatal slices from the irreversible loss of corticostriatal field potential (FP) amplitude via a GABA-mediated mechanism. Conversely, this drug showed no protection against 3-NP and ischemia-induced toxicity.Our data indicate that relatively high doses of ZNS are required to decrease striatal neuronal excitability while low concentrations of this drug are sufficient to protect striatum against mitochondrial impairment suggesting its possible use in the therapy of basal ganglia neurodegenerative diseases.     

Intrastriatal quinolinic acid injections protect against 6-hydroxydopamine-induced lesions of the dopaminergic nigrostriatal system

We tested the effect of intrastriatal quinolinic acid (QA) injections 2 weeks before subsequent intrastriatal injections of 6-hydroxydopamine (6-OHDA). Levels of DA and its metabolites were measured 2 days and 21 days after lesioning the dopaminergic nigrostriatal system with 6-OHDA. Intrastriatal 6-OHDA injections in the absence of prior treatment of QA significantly decreased dopamine (DA) and its metabolite levels in striatum but not in substantia nigra at day 2, and in striatum and substantia nigra at day 21, a clear indication of a time-dependent retrograde axonal degeneration of substantia nigra cell bodies. Intrastriatal QA injections 2 weeks before subsequent intrastriatal injection of 6-OHDA partially prevented the 6-OHDA-depleting effect on DA and its metabolite levels in both striatum and substantia nigra 21 days after 6-OHDA injection. However, no statistically significant differences were found between QA + 6-OHDA- and 6-OHDA-treated animals at day 2. Our results suggest that intrastriatal QA injections partially prevent the naturally-occurring retrograde axonal degeneration of substantia nigra cell bodies caused by 6-OHDA, and illustrate a target-derived interaction between dopaminergic nerve endings and cell bodies. We suggest that the protective effect found in the QA-injected animals against the neurotoxic action of 6-OHDA is mediated by neurotrophic agents released by activated astroglia.     

The vulnerability of striatal projection neurons and interneurons to excitotoxicity is differentially regulated by dopamine during development

The maturation of striatal projection neurons and interneurons is influenced by the development and integrity of their connectivity. In the present work, we have analyzed the modulation of striatum vulnerability to quinolinate (QUIN)-induced excitotoxicity in different neuronal populations by the nigrostriatal dopaminergic pathway during postnatal development. A single striatal lesion with 6-hydroxydopamine (6-OHDA) at the second postnatal day (P) 2 or QUIN at P7 induced a reduction in the striatal volume at P30, whereas an additive effect was observed when these two lesions were performed in the same animal. The analysis of different striatal neuronal populations showed that the excitotoxic lesion induced by QUIN over projection neurons stained with calbindin was partially reverted by the previous injection of 6-OHDA at P2. However, cholinergic interneurons were affected neither by the lack of dopamine innervation nor by QUIN treatment. This neuronal population also remained intact after the double lesion. In contrast, the number of other type of striatal interneurons, parvalbumin-positive neurons, were reduced by the dopaminergic ablation and also by the QUIN-induced excitotoxicity and this effect was additive after the double lesion when it was measured at P30. On the other hand, we studied the effect on the striatal outputs measuring the density of substance P-positive fibers in the substantia nigra and enkephalin-positive fibers in the globus pallidus. A reduction in substance P-positive fibers was observed in 6-OHDA injected animals, while the density of enkephalin-positive fibers was only decreased after QUIN treatment. The double lesion did not modify the effects of the single lesions. In conclusion, our results show that dopamine modulates the vulnerability to excitotoxicity during striatal postnatal development, and this effect is specific for projection neurons. Furthermore, striatonigral and striatopallidal pathways are differentially regulated by the activation of dopamine or glutamate receptors.     

Substance P release from knee joint afferent terminals: modulation by opioids

Perfusate obtained from the intra-articular space of the knee (100 microliters/min) in the halothane-anesthetized cat under resting conditions shows no detectable substance P-like immunoreactivity (SP-LI: less than 2 pg/20 min). Antidromic activation by electrical stimulation of the sciatic nerve at stimulus intensities which evoke activity in A beta/A delta/C but not A beta fibers or the local administration of capsaicin (10(-4) M) into the intra-articular perfusate results in a stimulus-dependent increase in the levels of SP-LI in the perfusate. This release is diminished in a naloxone-(1 mg/kg, i.v.) reversible fashion by sufentanil, D-Ala2-D-Leu5-enkephalin, and D-Pen2-D-Pen5-enkephalin, but not by U50488H (10(-4) M) added to the intra-articular perfusate. These observations thus suggest that the peripheral stores of SP-LI in small primary afferents are subject to release by antidromic activity and this release is subject to modulation by mu/delta receptors on these peripheral terminals.     

17β-Estradiol protects against NMDA-induced excitotoxicity by direct inhibition of NMDA receptors

Several lines of evidence suggest that 17β-estradiol (βE₂) has neuroprotective properties. The risk and severity of dementia are decreased in women who have received estrogen therapy, and βE₂ protects neurons in vitro against death from a variety of stressors. Neuroprotection by βE₂ has been suggested to be due to free radical scavenging. We demonstrate an additional neuroprotective mechanism whereby βE₂ protects against NMDA-induced neuronal death by directly inhibiting the NMDA receptor.     

Occurrence and distribution of substance P receptors in the cerebral blood vessels of the rat

The distribution of immunoreactivity to the receptor for substance P was examined in the cerebral blood vessels of the rat. Substance P immunoreactivity has been demonstrated in the nerve fibers of the cerebral blood vessels. Recently, the production of substance P receptor specific antibody has enabled the detection of localization of the substance P receptor in the central nervous system. In this study, we examined the existence of nerve fibers with substance P receptor immunoreactivity in the cerebral blood vessels and the cranial ganglia innervating the cerebral blood vessels. Sprague–Dawley rats were perfused with fixative and the pial arteries and the cranial ganglia known to innervate the cerebral blood vessels, i.e., trigeminal, sphenopalatine, internal carotid, otic and superior cervical ganglia, were dissected. All specimens were incubated with anti-substance P receptor IgG, then stained by the avidin–biotin–peroxidase complex method. Numerous nerve fibers with varicosities forming plexuses, with substance P receptor immunoreactivity were observed on the walls of the major extracerebral arteries forming the circle of Willis and its branches. Substance P receptor immunoreactivity was also detected in the endothelium of the cerebral arteries. Substance P receptor immunoreactivity was positive in many neurons of the sphenopalatine ganglion, otic ganglion, trigeminal ganglion, superior cervical ganglion and internal carotid ganglion. The present study demonstrated the existence of nerve fibers with substance P receptor immunoreactivity in the cerebral blood vessels and the cranial ganglia that innervate the cerebral blood vessels. These findings are important in understanding the responsiveness of the cerebral blood vessels to substance P.     

Effect of Substance P on uterine mast cell cytokine release during the reproductive cycle

There is increasing evidence that neuropeptides, steroid hormones and inflammatory cytokines influence the immune response during the reproductive cycle. In the present study, we focus on the effects of neuropeptide Substance P (SP) during the pre-implantation stage of embryo development (day 4 of pregnancy), at pro-estrus and di-estrus (two phases with different hormonal states). We found heterogeneous responses to SP and anti-IgE by the rat uterine mast cells (MCs), as detected by ELISA. In fact, MCs purified from uteri on day 4 of pregnancy released histamine, granulocyte macrophage-colony stimulating factor (GM-CSF) and tumor necrosis factor-alpha (TNF-) in response to anti-IgE, but not to SP. When pre-incubated with SP, the release to anti-IgE was significantly enhanced compared to anti-IgE alone. Exposure of SP to antibodies to SP, prior to pre-incubation with MCs, negated the SP effect on IgE-mediated release. At the pro-estrus phase SP showed similar behavior as on day 4 of pregnancy, whereas at the di-estrus phase SP alone was capable of inducing release of histamine and cytokines from purified uterine MCs. Moreover, non-quantitative RT-PCR analysis of the TNF- mRNA level suggested an SP stimulation at the di-estrus phase, but neither on day 4 of pregnancy nor at the pro-estrus phase. Taken together, these data strongly suggest that SP can modulate IgE-mediated uterine MC release of histamine and inflammatory cytokines in different ways, depending on the phase of the reproductive cycle.     

Substance P promotes lymphocyte-endothelial cell adhesion preferentially via LFA-1/ICAM-1 interactions

Substance P (SP), an 11 amino acid peptide, is released by C and A delta sensory nerve fibers during tissue insult and inflammation. We investigated the effect of SP on the expression and avidity of adhesion molecules, on lymphocytes and endothelial cells, which are central to the inflammatory cascade. Using in vitro adhesion assays we found that pretreatment of murine endothelial cells with SP enhanced their adhesiveness to splenocytes, the murine T cell hybridoma EL4 and nylon-enriched primary murine T cell in a dose and time dependent manner, the optimum dose being 10⁻¹⁰ M and the optimum time 6 h. SP at 10⁻¹⁰ M was also able to stimulate the splenocytes, EL4 T cells and primary T cells to enhance their adhesiveness for endothelial cells. The increased adhesiveness was associated with enhanced expression of ICAM-1 on endothelial cells and increased avidity of LFA-1 on lymphocytes. Further SP was chemotactic for T cells. These data suggest that SP modulates lymphocyte-endothelial cell interactions by preferentially upregulating LFA-1 and ICAM-1 interactions.